Lipid assessment forms part of routine healthcare assessments of the general population, primarily to identify the risk of atherosclerotic cardiovascular disease (ASCVD). It is recommended that these values are monitored over time, and reference ranges have been established for total cholesterol, HDL-C and LDL-C. Based on evidence of the clinical benefits of reducing LDL-C levels, guidelines provide recommendations for optimally managing people with dyslipidaemia. However, until recently, no attention was given to non-high-density lipoprotein cholesterol (non-HDL-C), despite the fact that it encompasses all plasma lipoproteins, including LDL, triglyceride-rich lipoproteins (TRL), TRL remnants, and lipoprotein(a) (Lp(a)) [1,2].
